Carbamazepine (All indications)

Macrosomia (> 4000g)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9776
R34959		 Coste (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 Weight at birth (≥3500 g) during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 1.18 [0.96;1.44] C
excluded (control group) 		175/502   911/2,916 1,086 502
ref
S9777
R34977		 Coste (Carbamazepine) (Controls unexposed, NOS) (Mixed indications), 2020 Weight at birth (≥3500 g) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.00 [0.83;1.21] C 158/468   576,301/1,707,707 576,459 468
ref
S9669
R34419		 Kini (Carbamazepine) (Controls unexposed, sick), 2006 Birth weight >4000 g during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No 0.88 [0.36;2.15] C 10/94   12/101 22 94
ref
S9616
R34188		 Endo (Carbamazepine) (Controls unexposed, sick), 2004 Birth weight > 4,000g throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 0.07 [0.00;8.55] C 0/8   0/1 0 8
ref
Total 3 studies 0.99 [0.82;1.20] 576,481 570
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Coste (Carbamazepine) (Controls unexposed, NOS) (Mixed indications), 2020Coste, 2020 1 1.00[0.83; 1.21]576,45946895%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: moderateROB mesure: moderateROB reporting: moderate Kini (Carbamazepine) (Controls unexposed, sick), 2006Kini, 2006 2 0.88[0.36; 2.15]22944%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: unclearROB mesure: moderateROB reporting: moderate Endo (Carbamazepine) (Controls unexposed, sick), 2004Endo, 2004 3 0.07[0.00; 8.55]080%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 0.99[0.82; 1.20]576,4815700.05.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine) (Controls unexposed, NOS) (Mixed indications; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.99[0.82; 1.20]576,4815700%NACoste (Carbamazepine) (Controls unexposed, NOS) (Mixed indications), 2020 Kini (Carbamazepine) (Controls unexposed, sick), 2006 Endo (Carbamazepine) (Controls unexposed, sick), 2004 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.00[0.83; 1.21]576,459468 -NACoste (Carbamazepine) (Controls unexposed, NOS) (Mixed indications), 2020 1 unexposed, sickunexposed, sick 0.76[0.24; 2.45]221025%NAKini (Carbamazepine) (Controls unexposed, sick), 2006 Endo (Carbamazepine) (Controls unexposed, sick), 2004 2 Tags Adjustment   - No  - No 0.99[0.82; 1.20]576,4815700%NACoste (Carbamazepine) (Controls unexposed, NOS) (Mixed indications), 2020 Kini (Carbamazepine) (Controls unexposed, sick), 2006 Endo (Carbamazepine) (Controls unexposed, sick), 2004 3 All studiesAll studies 0.99[0.82; 1.20]576,4815700%NACoste (Carbamazepine) (Controls unexposed, NOS) (Mixed indications), 2020 Kini (Carbamazepine) (Controls unexposed, sick), 2006 Endo (Carbamazepine) (Controls unexposed, sick), 2004 30.05.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9776

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.00[0.83; 1.21]576,459468 -NACoste (Carbamazepine) (Controls unexposed, NOS) (Mixed indications), 2020 1 unexposed, sick controlsunexposed, sick controls 0.76[0.24; 2.45]221025%NAKini (Carbamazepine) (Controls unexposed, sick), 2006 Endo (Carbamazepine) (Controls unexposed, sick), 2004 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.18[0.96; 1.44]1,086502 -NACoste (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 10.510.01.0